AACR Journals
@aacrjournals.bsky.social
The American Association for Cancer Research’s 10 peer-reviewed journals provide a renowned, respected forum for publishing the most innovative cancer science, encompassing the full spectrum of basic, translational, clinical, and epidemiological research.
Recently posted in Cancer Immunology Research: Neoadjuvant Immunotherapy Promotes the Formation of Mature Tertiary Lymphoid Structures in a Remodeled Pancreatic Tumor Microenvironment buff.ly/yxK4Xpr
Neoadjuvant Immunotherapy Promotes the Formation of Mature Tertiary Lymphoid Structures in a Remodeled Pancreatic Tumor Microenvironment
The authors present a spatial multi-omics atlas of TLS-positive pancreatic ductal adenocarcinomas from patients treated with neoadjuvant immunotherapy, revealing that pathologic responses are…
doi.org
November 26, 2025 at 5:05 PM
Recently posted in Cancer Immunology Research: Neoadjuvant Immunotherapy Promotes the Formation of Mature Tertiary Lymphoid Structures in a Remodeled Pancreatic Tumor Microenvironment buff.ly/yxK4Xpr
New in Blood Cancer Discovery: IRF4 Shapes the #Lymphoma TME buff.ly/7wbtXW8
Elevated IRF4 expression in #follicularlymphoma cells may contribute to immune evasion and aggressive disease features by impairing B-cell antigen presentation, altering cytokine signaling, and rewiring metabolism.
Elevated IRF4 expression in #follicularlymphoma cells may contribute to immune evasion and aggressive disease features by impairing B-cell antigen presentation, altering cytokine signaling, and rewiring metabolism.
IRF4 Promotes Immune Evasion and Shapes the Tumor Microenvironment in Follicular Lymphoma
Elevated IRF4 expression in follicular lymphoma cells may contribute to immune evasion and aggressive disease features by impairing B-cell antigen presentation, altering cytokine signaling, and…
buff.ly
November 25, 2025 at 5:07 PM
New in Blood Cancer Discovery: IRF4 Shapes the #Lymphoma TME buff.ly/7wbtXW8
Elevated IRF4 expression in #follicularlymphoma cells may contribute to immune evasion and aggressive disease features by impairing B-cell antigen presentation, altering cytokine signaling, and rewiring metabolism.
Elevated IRF4 expression in #follicularlymphoma cells may contribute to immune evasion and aggressive disease features by impairing B-cell antigen presentation, altering cytokine signaling, and rewiring metabolism.
Cancer Discovery News: Highlighting Must-Read Industry News. buff.ly/hNe0xKN
November 24, 2025 at 4:03 PM
Cancer Discovery News: Highlighting Must-Read Industry News. buff.ly/hNe0xKN
In the November 1 issue of Clinical Cancer Research, read the Phase 1 Study: Izalontamab in advanced epithelial tumor.
Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
AbstractPurpose:. Izalontamab (SI-B001) is a novel EGFR×HER3 bispecific antibody. This first-in-human phase I study presents the safety and pharmacokinetics of izalontamab.Patients and Methods:.…
buff.ly
November 22, 2025 at 5:01 PM
In the November 1 issue of Clinical Cancer Research, read the Phase 1 Study: Izalontamab in advanced epithelial tumor.
Check out the brand new commentary in Blood Cancer Discovery buff.ly/s1XKgeR
Beyond Expansion: Tumor Debulking as Key to Improving CAR T-Cell Potential in Lymphoma
Beyond Expansion: Tumor Debulking as Key to Improving CAR T-Cell Potential in Lymphoma
November 21, 2025 at 10:43 PM
Check out the brand new commentary in Blood Cancer Discovery buff.ly/s1XKgeR
Beyond Expansion: Tumor Debulking as Key to Improving CAR T-Cell Potential in Lymphoma
Beyond Expansion: Tumor Debulking as Key to Improving CAR T-Cell Potential in Lymphoma
Not only do AACR Members receive a 10% discount on publishing fees, but some AACR scientific working groups offer additional discounts on top of this. Learn more: buff.ly/12PgSmX
November 21, 2025 at 7:51 PM
Not only do AACR Members receive a 10% discount on publishing fees, but some AACR scientific working groups offer additional discounts on top of this. Learn more: buff.ly/12PgSmX
The Clinical Cancer Research Early Career Award recognizes outstanding early career investigators who have authored original articles published in the journal that have made a significant impact in one or more of the fields represented by the journal.
Nominations are open!
Nominations are open!
Early Career Award | Clinical Cancer Research | American Association for Cancer Research
Early Career Award | Clinical Cancer Research | American Association for Cancer Research .aacrcontent .banner{ width: 100% margin: -20px; } .aacrcontent .banner-sm{ display: none; } .right{float:…
buff.ly
November 21, 2025 at 2:03 PM
The Clinical Cancer Research Early Career Award recognizes outstanding early career investigators who have authored original articles published in the journal that have made a significant impact in one or more of the fields represented by the journal.
Nominations are open!
Nominations are open!
When you submit to an AACR Journal, you'll benefit from rapid decision and publication times. Learn more about the Manuscript Turnaround Guarantee for Active AACR Members: buff.ly/KP7I5Z6
November 20, 2025 at 7:43 PM
When you submit to an AACR Journal, you'll benefit from rapid decision and publication times. Learn more about the Manuscript Turnaround Guarantee for Active AACR Members: buff.ly/KP7I5Z6
Molecular Cancer Therapeutics is the central hub for #FirstDisclosures of novel cancer therapeutics. Catch up on the latest articles: buff.ly/4JBMh5y
November 20, 2025 at 2:55 PM
Molecular Cancer Therapeutics is the central hub for #FirstDisclosures of novel cancer therapeutics. Catch up on the latest articles: buff.ly/4JBMh5y
"Editors and staff are fantastic to interact with. It is always easy to reach out, get feedback and suggestions." -Sandra Misale, Cancer Discovery Author
See more of what our authors are saying about publishing with the Journals. buff.ly/7x8ra8e
See more of what our authors are saying about publishing with the Journals. buff.ly/7x8ra8e
November 19, 2025 at 5:07 PM
"Editors and staff are fantastic to interact with. It is always easy to reach out, get feedback and suggestions." -Sandra Misale, Cancer Discovery Author
See more of what our authors are saying about publishing with the Journals. buff.ly/7x8ra8e
See more of what our authors are saying about publishing with the Journals. buff.ly/7x8ra8e
The Cancer Research Early Career Award recognizes outstanding early career investigators who have authored peer-reviewed, original articles published in the journal that have made a significant impact in one or more of the fields represented by the journal.
Nominations are open!
Nominations are open!
Cancer Research Early Career Award | Cancer Research | American Association for Cancer Research
Cancer Research Early Career Award | Cancer Research | American Association for Cancer Research .aacrcontent .banner{ width: 100% margin: -20px; } .aacrcontent .banner-sm{ display: none; }…
buff.ly
November 19, 2025 at 2:08 PM
The Cancer Research Early Career Award recognizes outstanding early career investigators who have authored peer-reviewed, original articles published in the journal that have made a significant impact in one or more of the fields represented by the journal.
Nominations are open!
Nominations are open!
Read this recent In Focus article in Blood Cancer Discovery, The Global State of Blood Cancers: An Ongoing Challenge by @lilliansiu.bsky.social buff.ly/lzyYvgE
November 18, 2025 at 10:10 PM
Read this recent In Focus article in Blood Cancer Discovery, The Global State of Blood Cancers: An Ongoing Challenge by @lilliansiu.bsky.social buff.ly/lzyYvgE
Read this collection of impactful Blood Cancer Discovery articles that highlight advanced lymphoma research by leveraging novel tools and techniques, uncovering molecular networks that drive oncogenesis and progression, and bringing innovative therapies to patients. buff.ly/q3NmZc2
November 18, 2025 at 10:05 PM
Read this collection of impactful Blood Cancer Discovery articles that highlight advanced lymphoma research by leveraging novel tools and techniques, uncovering molecular networks that drive oncogenesis and progression, and bringing innovative therapies to patients. buff.ly/q3NmZc2
In the November 1 issue of Clinical Cancer Research, Immune MRD in MM patients on lenalidomide maintenance.
Immune MRD Status Informs Tumor MRD Outcome Prognostication in Patients with Multiple Myeloma on Lenalidomide Maintenance
AbstractPurpose:. Lenalidomide (Len) maintenance is the most frequently utilized approach for newly diagnosed patients with multiple myeloma following induction therapy with/without consolidative…
buff.ly
November 18, 2025 at 5:02 PM
In the November 1 issue of Clinical Cancer Research, Immune MRD in MM patients on lenalidomide maintenance.
Read article collections featuring impactful, cutting-edge research on Tumor Metabolism, Cancer Health Disparities, and more: buff.ly/Oi8by86
November 17, 2025 at 4:18 PM
Read article collections featuring impactful, cutting-edge research on Tumor Metabolism, Cancer Health Disparities, and more: buff.ly/Oi8by86
The Cancer Discovery Early Career Award recognizes outstanding early career investigators who have authored peer-reviewed, original articles published in the journal that have made a significant impact in one or more of the fields represented by the journal.
Nominations are open! buff.ly/jUwZsdd
Nominations are open! buff.ly/jUwZsdd
November 17, 2025 at 2:33 PM
The Cancer Discovery Early Career Award recognizes outstanding early career investigators who have authored peer-reviewed, original articles published in the journal that have made a significant impact in one or more of the fields represented by the journal.
Nominations are open! buff.ly/jUwZsdd
Nominations are open! buff.ly/jUwZsdd
New article type from Cancer Epidemiology, Biomarkers & Prevention: The Resource Report covers major population-focused data resources, including cohorts, consortia, networks, registries, and other valuable datasets.
➡️Read the collection: buff.ly/MFoGugc
➡️Submit a Resource Report: buff.ly/FEFJy8y
➡️Read the collection: buff.ly/MFoGugc
➡️Submit a Resource Report: buff.ly/FEFJy8y
November 16, 2025 at 5:02 PM
New article type from Cancer Epidemiology, Biomarkers & Prevention: The Resource Report covers major population-focused data resources, including cohorts, consortia, networks, registries, and other valuable datasets.
➡️Read the collection: buff.ly/MFoGugc
➡️Submit a Resource Report: buff.ly/FEFJy8y
➡️Read the collection: buff.ly/MFoGugc
➡️Submit a Resource Report: buff.ly/FEFJy8y
This Cancer Immunology Research article shows that biparatopic CARs targeting dual epitopes of TROP2 overcome the resistance seen to current TROP2-targeted ADCs, highlighting the potential of rational structure-based CAR engineering to overcome resistance to antibody-based therapies in solid tumors.
Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
The authors show that biparatopic CARs targeting dual epitopes of TROP2 overcome the resistance seen to current TROP2-targeted ADCs, highlighting the potential of rational structure-based CAR…
doi.org
November 15, 2025 at 5:02 PM
This Cancer Immunology Research article shows that biparatopic CARs targeting dual epitopes of TROP2 overcome the resistance seen to current TROP2-targeted ADCs, highlighting the potential of rational structure-based CAR engineering to overcome resistance to antibody-based therapies in solid tumors.
Did you know - AACR Journals offers simultaneous publication opportunities. Contact Karen Honey, Executive Editor of Cancer Immunology Research, about submitting your related manuscript: [email protected]
Submit an abstract by December 1 for the AACR IO Conference on Discovery and Innovation in Cancer Immunology (February 18-21, 2026; Los Angeles), chaired by Nina Bhardwaj and Antoni Ribas. Learn more:
buff.ly/TUarANa
#AACRIO26
buff.ly/TUarANa
#AACRIO26
November 14, 2025 at 8:34 PM
Did you know - AACR Journals offers simultaneous publication opportunities. Contact Karen Honey, Executive Editor of Cancer Immunology Research, about submitting your related manuscript: [email protected]
Learn how AACR’s #openaccess, peer-reviewed journal—Cancer Research Communications—supports authors from presubmission through publication: buff.ly/NTCCGgR
November 14, 2025 at 5:59 PM
Learn how AACR’s #openaccess, peer-reviewed journal—Cancer Research Communications—supports authors from presubmission through publication: buff.ly/NTCCGgR
📣 New collection alert!
Advances in Targeted Protein Degradation: PROTACs and Molecular Glues buff.ly/xdWDulw
This collection features recent research and review articles highlighting key advances in PROTAC and molecular glue development.
Advances in Targeted Protein Degradation: PROTACs and Molecular Glues buff.ly/xdWDulw
This collection features recent research and review articles highlighting key advances in PROTAC and molecular glue development.
November 12, 2025 at 5:05 PM
📣 New collection alert!
Advances in Targeted Protein Degradation: PROTACs and Molecular Glues buff.ly/xdWDulw
This collection features recent research and review articles highlighting key advances in PROTAC and molecular glue development.
Advances in Targeted Protein Degradation: PROTACs and Molecular Glues buff.ly/xdWDulw
This collection features recent research and review articles highlighting key advances in PROTAC and molecular glue development.
New in Blood Cancer Discovery: Cancer Cell–Intrinsic CAR T Resistance in #DLBCL
Acquisition of DLBCL-intrinsic CD19 CAR-T cell therapy resistance in cell lines identifies a cross-antigen resistant phenotype with a gene signature predictive of clinical CAR-T response. Read more:
Acquisition of DLBCL-intrinsic CD19 CAR-T cell therapy resistance in cell lines identifies a cross-antigen resistant phenotype with a gene signature predictive of clinical CAR-T response. Read more:
DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response
Acquisition of DLBCL-intrinsic CD19 CAR-T cell therapy resistance in cell lines identifies a cross-antigen resistant phenotype with a gene signature predictive of clinical CAR-T response.
buff.ly
November 11, 2025 at 5:04 PM
New in Blood Cancer Discovery: Cancer Cell–Intrinsic CAR T Resistance in #DLBCL
Acquisition of DLBCL-intrinsic CD19 CAR-T cell therapy resistance in cell lines identifies a cross-antigen resistant phenotype with a gene signature predictive of clinical CAR-T response. Read more:
Acquisition of DLBCL-intrinsic CD19 CAR-T cell therapy resistance in cell lines identifies a cross-antigen resistant phenotype with a gene signature predictive of clinical CAR-T response. Read more:
From the November issue of Cancer Immunology Research, check out Tunneling CARs: Increasing CAR T-Cell Tumor Infiltration through the Overexpression of MMP-7 and Osteopontin-b
Tunneling CARs: Increasing CAR T-Cell Tumor Infiltration through the Overexpression of MMP-7 and Osteopontin-b
Inadequate CAR T-cell infiltration into solid tumors limits efficacy. The authors show that engineering CAR T cells to express osteopontin can overcome physical barriers in solid tumors, offering a…
doi.org
November 11, 2025 at 2:16 PM
From the November issue of Cancer Immunology Research, check out Tunneling CARs: Increasing CAR T-Cell Tumor Infiltration through the Overexpression of MMP-7 and Osteopontin-b
Robert Kruger, PhD, Senior Executive Editor of Cancer Discovery, joined Zhongshan Hospital Assistant President Qiang Gao, PhD, to chair the opening session of the 2025 CACA Cancer Discovery Symposium at CCHIO 2025. We thank all of the speakers for their contributions to an outstanding program.
November 10, 2025 at 4:11 PM
Robert Kruger, PhD, Senior Executive Editor of Cancer Discovery, joined Zhongshan Hospital Assistant President Qiang Gao, PhD, to chair the opening session of the 2025 CACA Cancer Discovery Symposium at CCHIO 2025. We thank all of the speakers for their contributions to an outstanding program.
Sign up to receive alerts directly to your inbox to keep up with the latest published issues: buff.ly/O6OYSDp
November 10, 2025 at 4:08 PM
Sign up to receive alerts directly to your inbox to keep up with the latest published issues: buff.ly/O6OYSDp